Advertisement
Advertisement

AMLX

AMLX logo

Amylyx Pharmaceuticals, Inc. Common Stock

17.59
USD
Sponsored
+0.02
+0.11%
Apr 21, 15:59 UTC -4
Closed
exchange

After-Market

17.93

+0.34
+1.93%

AMLX Earnings Reports

Positive Surprise Ratio

AMLX beat 8 of 17 last estimates.

47%

Next Report

Date of Next Report
May 07, 2026
Estimate for Q1 26 (Revenue/ EPS)
--
/
-$0.33
Implied change from Q4 25 (Revenue/ EPS)
--
/
+10.00%
Implied change from Q1 25 (Revenue/ EPS)
--
/
-21.43%

Amylyx Pharmaceuticals, Inc. Common Stock earnings per share and revenue

On Mar 03, 2026, AMLX reported earnings of -0.30 USD per share (EPS) for Q4 25, beating the estimate of -0.36 USD, resulting in a 18.03% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -7.78% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 6 analysts forecast an EPS of -0.33 USD, with revenue projected to reach -- USD, implying an increase of 10.00% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Evotec SE - ADR
Report Date
Apr 08, 2026 For Q4 25
Estimate
$0.31
Actual
$0.08
Surprise
-74.45%
logo
Vivos Therapeutics, Inc. Common Stock
Report Date
Apr 15, 2026 For Q4 25
Estimate
-$0.49
Actual
-$0.57
Surprise
-17.65%
logo
Traws Pharma, Inc. Common Stock
Report Date
Apr 15, 2026 For Q4 25
Estimate
-$1.24
Actual
$0.63
Surprise
+150.46%
logo
Cosmos Holdings Inc. Common Stock
Report Date
Apr 15, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.31
Surprise
-659.80%
logo
BIOMERICA INC
Report Date
Apr 13, 2026 For Q3 26
Estimate
-
Actual
-$0.44
Surprise
-
FAQ
For Q4 2025, Amylyx Pharmaceuticals, Inc. Common Stock reported EPS of -$0.30, beating estimates by 18.03%, and revenue of $0.00, 0% as expectations.
The stock price moved down -7.78%, changed from $15.30 before the earnings release to $14.11 the day after.
The next earning report is scheduled for May 07, 2026.
Based on 6 analysts, Amylyx Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$0.33 and revenue of -- for Q1 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement